The hallmarks of symptomatic human monocytic ehrlichiosis (HME) include fever, headache, myalgia, nausea, malaise, transaminitis, and blood cell abnormalities. Previous case reports have described isolated cranial nerve palsies in infected patients but not hearing loss. We describe the onset of sudden sensorineural hearing loss in 2 patients with HME-a 31-year-old woman and an 82-year-old woman. The older patient experienced objective and subjective improvement in her hearing after treatment with an antibiotic and steroid taper; the younger patient was lost to audiologic follow-up. Additionally, we discuss the possible mechanisms of the hearing loss in these patients.
Introduction
Human monocytic ehrlichiosis (HME) is one of the most common, potentially life-threatening tickborne illnesses in the United States. 1, 2 Its causative agent, Ehrlichia chaffeensis, is an obligate intracellular, gram-negative bacterium that typically invades and replicates in host mononuclear phagocytes, as the infection's name implies.
Nearly one-third of HME cases occur in Missouri, Arkansas, and Oklahoma due to that area's high prevalence of its vector, the lone-star tick (Amblyomma americanum). 3 Most infected patients have a subclinical presentation. In endemic areas, seroprevalence rates as high as 22% have been reported in asymptomatic children. 4 The hallmarks of symptomatic infection are fever, headache, myalgia, nausea, malaise, transaminitis, thrombocytopenia, and leukopenia. 5 In rare cases, especially in immunocompromised patients, ehrlichiosis can present with fulminant features and multisystem organ dysfunction and sometimes result in death. [6] [7] [8] Some 20% of HME patients present with meningitis or encephalitis. Isolated cranial nerve palsies affecting the trochlear nerve 9 and the facial nerve 10 also have been reported. However, to the best of our knowledge, no case of HME-associated hearing loss has been previously described in the literature. In this article, we describe 2 cases of symptomatically worsening sudden sensorineural hearing loss (SNHL) that arose in patients with E chaffeensis infection.
Case reports Patient 1. A 31-year-old woman from southeastern
Kansas with a history of chronic sinusitis presented to her primary care physician for treatment of headache. Examination findings were unremarkable at that time, and the patient was treated conservatively for uncomplicated sinonasal disease. However, her condition worsened over the next week as she began to experience fevers. She was started on amoxicillin/clavulanic acid for presumed bacterial sinusitis.
When the patient's condition continued to worsen the following day, she presented to a local emergency department. She reported significant tick exposure, as she lived on a farm. Physical examination revealed an alert, febrile woman in mild distress, but findings were otherwise unremarkable. Laboratory evaluation revealed the presence of transaminitis, leukopenia, and an elevated alkaline phosphatase level. A lumbar puncture revealed clear and unremarkable cerebrospinal fluid (CSF) and a normal opening pressure.
The patient was to be admitted to the intensive care unit (ICU) for the treatment of sepsis, but findings on computed tomography (CT) of the head were concerning for a subarachnoid hemorrhage. Therefore, she was transferred by air to our facility in northeast Kansas for neurosurgical evaluation and management.
Upon arrival, the patient was admitted to our ICU. However, CT angiography of the head and neck revealed no intracranial hemorrhage, aneurysm, or arteriovenous malformation.
Absent a finding of intracranial hemorrhage, the patient was transferred to the internal medicine service, and the focus of her treatment was shifted toward tick-borne diseases. The infectious disease team was consulted, and oral doxycycline was started empirically. Serologic tests for tick-borne diseases were performed. A peripheral smear to identify morulae was negative. Four days after the patient's admission, a polymerase chain reaction (PCR) assay was found to be positive for E chaffeensis and negative for other tick-borne organisms.
Meanwhile, the patient continued to experience headaches that were postural in nature. An epidural blood patch was performed to repair a CSF leak that had developed after the lumbar puncture.
The ENT service was then asked to interview the patient to evaluate a 1-week history of otalgia, hearing loss, aural fullness, and a buzzing sound. Findings on otoscopy and a cranial nerve examination were normal. The next day, we performed audiometry, which revealed a type A tympanogram with a new-onset moderate, low-frequency, left-sided SNHL; her hearing levels rose to within normal limits in the higher frequencies (figure 1). Word recognition thresholds were the same in both ears.
The patient eventually defervesced and experienced a notable alleviation of her headache and myalgias. She was discharged home 1 week after admission on oral doxycycline. She was asked to follow up at a local ENT clinic for repeat audiometry and electrocochleography, but she did not and she was lost to follow-up. Patient 2. An 82-yearold woman from eastern Kansas with history of benign paroxysmal positional vertigo (BPPV), hypertension, and hypothyroidism presented to her primary care physician with a 1-day history of fevers and chills. The patient reported that she had received 50 tick bites during the previous year. Her primary concern was Lyme disease. She was prescribed doxycycline and instructed to follow up in 1 week.
The patient did not take the doxycycline, and 4 days after her visit she presented to a local emergency department complaining of myalgias, headache, fevers, chills, weakness, nausea, and vomiting. With the exception of fever, findings on physical examination were unremarkable. A complete blood count demonstrated leukopenia, and a complete metabolic panel indicated acute kidney injury and elevated liver enzyme levels. Her urinalysis was suggestive of a urinary tract infection (UTI), and she was admitted for intravenous antibiotics and fluid resuscitation.
The patient continued to spike fevers despite being empirically treated with ceftriaxone for the UTI. Testing revealed that her leukocyte and platelet counts continued to drop. The infectious disease service was consulted, and the patient was switched back to doxycycline for a presumptive tick-borne disease. More serologic measurements were obtained.
On hospital day 3, the patient began defervescing, but she continued to complain of severe headache. Findings on CT of the head were unremarkable. The next day, her headache had subsided somewhat. She was discharged on hospital day 4 and managed with outpatient analgesia. After discharge, her laboratory tests detected IgG antibodies for Rocky Mountain spotted fever and no antibodies for E chaffeensis. However, her PCR assay was positive for E chaffeensis DNA.
Seventeen days after discharge, the patient woke up with right-sided aural fullness, tinnitus, otalgia, a muffled sensation, and vertigo, which she attributed to her BPPV. She was unable to be seen in the ENT clinic or tested by an audiologist until 2 weeks later. Eventually, she underwent audiometry, which demonstrated a mild sloping to moderately severe hearing loss bilaterally, with a more pronounced low-frequency hearing loss on the right (figure 2). She was referred to our ENT department because of concerns over the SNHL, and she was seen there 4 days later.
At our ENT clinic, the patient was found to have normal tympanic membranes and cranial nerves, and a tuning-fork test was negative. She was started on a 14-day prednisone taper for SNHL and a repeat 10-day course of doxycycline to fend off potential ehrlichiosis. By the end of the 14 days, her tinnitus and otalgia had resolved. Repeat audiometry demonstrated bilaterally symmetric SNHL with an improvement in hearing on the affected (right) side ( figure 3 ).
Discussion
In addition to E chaffeensis, two other causes of ehrlichiosis are Anaplasma phagocytophilum, the causative organism in human granulocytic anaplasmosis, and Ehrlichia ewingii. While the latter two organisms differ from E chaffeensis primarily in their vectors and cellular targets (neutrophils), their clinical presentations are virtually indistinguishable. 11 Like HME, human granulocytic anaplasmosis has been associated with cranial nerve manifestations, as well as sensory deficits. 12, 13 The pathogenesis of neural impairment, particularly hearing impairment, in E chaffeensis infection is unknown.
In the 2 cases we describe, the patients both had subjectively age-appropriate hearing before their HME infections; they developed symptomatic hearing loss only after tick exposure. Neither patient had had a previous audiogram available to confirm an objective change in hearing thresholds, but having a baseline audiogram on hand for comparison is rather rare.
Neither patient had been exposed to ototoxic medications, nor did they have a history of excessive noise exposure. Neither patient had undergone an MRI, since their symptoms were temporally aligned with their bouts of HME. Their CTs did not demonstrate a lesion that could account for an acute SNHL. Therefore, the hearing loss in both patients was likely attributable to their E chaffeensis exposure.
It is possible that the mechanism of SNHL in these 2 patients was triggered by vasculitis secondary to E chaffeensis exposure. Grant et al reported a case of fatal seronegative HME. 10 Their patient developed facial nerve paralysis during his infectious course. Postmortem biopsies of the brain and meninges demonstrated a mild infiltrate of atypical lymphoid cells within the blood vessels of the leptomeninges. Stains demonstrated a reactive process that featured a predominance of T cells and no demonstration of clonality.
Because of her leukopenia, our patient 1 underwent flow cytometry on hospital day 2. It demonstrated a preponderance of atypical T cells and dropped CD4 + and CD8 + cells, which have been described anecdotally in Ehrlichia infections. 14 While this finding was confirmed only systemically in our patient 1, it is possible that the inflammatory process she exhibited also might have manifested within the cochlear vessels, which led to the SNHL.
Alternately, previously described immune dysregulation might have been the cause of our patients' SNHL. 2 In hepatic studies on patients affected with HME, Sehdev and Dumler found that even those who showed no evidence of active intracellular infection demonstrated injury. 15 These authors postulated that this finding might suggest an activation of host innate immunity or acquired immunity. Therefore, a direct autoimmune attack on the inner ear triggered by Ehrlichia infection rather than by the presence of a perivascular lymphopro-liferative infiltrate might have been the mechanism for the sudden SNHL in our patients.
Idiopathic SNHL may have a viral etiology. 16 Leukopenia is a hallmark of ehrlichiosis, and patients are theoretically immunocompromised during their infections. It is possible that in this vulnerable state, either our 2 patients contracted a virus or a latent virus reactivated, and this caused cochleitis or neuritis. This seems more plausible given the fact that our patient 2 developed SNHL after the administration of antibiotic therapy, when her symptoms had mostly resolved.
SNHL has several possible etiologies, including autoimmune, vascular, and infectious causes. Our report describes the development of sudden SNHL in patients infected with E chaffeensis. While neuropathies and central nervous system disturbances linked to HME have been described numerous times, to the best of our knowledge this is the first report of hearing loss in affected patients. Physicians who treat ehrlichiosis should question and examine all affected patients for cranial neuropathy and otologic and vestibular symptoms. most published literature since then has found that the incidence of malignancy arising a multinodular goiter is also notable, ranging from 7.5 to 21.2%. 6, 9, 13, 14 The incidence appears to be similar to that of solitary thyroid nodules. 10 Our finding that the overall incidence of cancer in multinodular goiter patients who had undergone surgery was 14.3% is comparable to that reported in other studies around the world. The incidence of cancer varied depending on the indication of surgery-15.9% for those who had undergone surgery for a suspected malignancy and 0% for those who had undergone surgery for other indications.
Given that (1) the incidence of malignancy in multinodular goiter is noteworthy and (2) there are numerous nodules in multinodular goiter, we must ask ourselves, Which nodules should we as clinicians focus our attention and evaluation efforts on? Should we focus on only the largest, dominant nodules, or should we evaluate all the nodules equally despite the attendant increase in cost?
Currently, it is widespread practice that physicians concentrate their attention on the dominant nodules while paying scant attention to the other, smaller nodules during the clinical evaluation and follow-up of multinodular goiter. 15 However, supporting evidence for this practice is conflicting. Frates et al 16 found that the incidence of cancer in the dominant nodule was 72.5%, and Paksoy et al 17 reported 64.2%. On the other hand, Erbil et al found that 59% of thyroid cancer foci lay within the nondominant nodule and 41% within the dominant nodule. 18 We found that the incidence of carcinoma arising from the nondominant nodule was 50.0%, which was similar to the incidence in the dominant nodule (44.4%).
We believe that this finding serves as a timely reminder to clinicians to assess nondominant nodules, even the small nodules, with the same care as dominant nodules during ultrasound and to perform fine-needle aspiration cytology accordingly.
Our experience supports the recommendation in the most recent American Thyroid Association guidelines 6 that all thyroid nodules larger than 1 cm should be evaluated and that all nodules that exhibit suspicious ultrasonographic features should be aspirated and sent for cytology.
To calculate the overall incidence of cancer in multinodular goiter would require that all patients with multinodular goiter be assessed, regardless of whether surgery is necessary. Unfortunately, as is the case with most tertiary care surgical centers, our endocrinology colleagues usually refer to us only those patients with multinodular goiter who have a clinical suspicion of cancer or a large enough goiter to cause compression or cosmetic issues. A sizable number of patients with multinodular goiter are not referred to us, and they are therefore unavailable for our assessment.
In our study, we evaluated the incidence of cancer in multinodular goiter only in patients who required surgery. Although our data collection might have been biased in terms of our examination of only a surgical population, we believe that our findings are still applicable because they are representative of a typical patient population seen in a surgical practice. Our results are especially useful for surgeons in terms of preoperative counseling. In addition, by breaking down the incidence of malignancy according to surgical indication (15.9% for suspected malignancy and 0% for other indications), our data provide clinicians with information to counsel each patient more precisely and relevantly.
In conclusion, the incidence of malignancy in multinodular goiter is appreciable, and clinicians should evaluate nodular thyroid disease the same way regardless of whether the patient has a solitary or a multinodular goiter. Moreover, smaller, nondominant nodules should be examined with the same amount of vigilance as are dominant nodules. 
